{
    "clinical_study": {
        "@rank": "94140", 
        "arm_group": [
            {
                "arm_group_label": "danegapetide high dose", 
                "arm_group_type": "Active Comparator", 
                "description": "7,5 mg bolus injection, followed by 22,5 mg infused over 6 hours"
            }, 
            {
                "arm_group_label": "danegaptide low dose", 
                "arm_group_type": "Active Comparator", 
                "description": "2,5 mg bolus injection, followed by 7,5 mg infused over 6 hours"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "bolus injection, followed by infused over 6 hours"
            }
        ], 
        "brief_summary": {
            "textblock": "This study explores the potential cardioprotective properties of danegaptide when\n      administered to patients with ST-Segment elevation myocardial infarction."
        }, 
        "brief_title": "Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction", 
        "condition": "STEMI", 
        "condition_browse": {
            "mesh_term": [
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 18 years\n\n          -  ST-segment elevation myocardial infarction\n\n          -  Acute onset of chest pain of < 12 hours duration\n\n        Exclusion Criteria:\n\n          -  Pregnancy\n\n          -  Known prior Myocardial Infarction in same area as present STEMI, known hypertrophic\n             or dilated cardiomyopathy, or prior  hospital admission for heart failure\n\n          -  Contraindication for cardiac MRI\n\n          -  Inability to understand information or provide informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01977755", 
            "org_study_id": "13-031"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "danegapetide high dose", 
                    "danegaptide low dose"
                ], 
                "intervention_name": "danegaptide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 27, 2013", 
        "location": {
            "contact": {
                "email": "thomas.engstrom@rh.regionh.dk", 
                "last_name": "Thomas Engstrom, MD, DMSci", 
                "phone": "004535458444"
            }, 
            "facility": {
                "address": {
                    "city": "Copenhagen", 
                    "country": "Denmark", 
                    "zip": "2100"
                }, 
                "name": "The Heart Center, Rigshospitalet, University of Copenhagen"
            }, 
            "investigator": {
                "last_name": "Thomas Engstrom, MD, DMSci", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess Clinical Efficacy and Safety of Danegaptide in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention", 
        "overall_contact": {
            "email": "thomas.engstrom@rh.regionh.dk", 
            "last_name": "Thomas Engstrom, MD, DMSci", 
            "phone": "004535458444"
        }, 
        "overall_official": {
            "affiliation": "The Heart Center, Rigshopitalet University of Copenhagen", 
            "last_name": "Thomas Engstrom, MD, DMSci", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Denmark: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Myocardial Salvage Index as assessed by MRI and calculated as the difference between myocardial volume at risk and final infarct size in relation to myocardial volume at risk", 
            "measure": "Myocardial Salvage Index", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01977755"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Relative Infarct size, Absolute Infarct size, Left Ventricular Ejection Fraction (LVEF), microvascular obstruction and infarct haemorrhage as determined by MRI", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Degree of ST-resolution and fraction of patients with 70 % ST-resolution measured by ECG 60 minutes post Percutaneous Coronary Intervention procedure", 
                "safety_issue": "No", 
                "time_frame": "60 minutes"
            }, 
            {
                "measure": "Major Clinical Adverse Events including cardiac death, new or worsening heart failure and re-admission for heart failure", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "source": "Zealand Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zealand Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}